KR102435383B1 - 글리피칸 에피토프 및 이의 용도 - Google Patents

글리피칸 에피토프 및 이의 용도 Download PDF

Info

Publication number
KR102435383B1
KR102435383B1 KR1020177022547A KR20177022547A KR102435383B1 KR 102435383 B1 KR102435383 B1 KR 102435383B1 KR 1020177022547 A KR1020177022547 A KR 1020177022547A KR 20177022547 A KR20177022547 A KR 20177022547A KR 102435383 B1 KR102435383 B1 KR 102435383B1
Authority
KR
South Korea
Prior art keywords
seq
epitope
delete delete
substituted
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177022547A
Other languages
English (en)
Korean (ko)
Other versions
KR20170109584A (ko
Inventor
더글러스 캠벨
아이린 저스티니아노 푸엔마요르
알린 노콘
줄리 순
콰 트루옹
브래들리 월시
산드라 위스뮬러
Original Assignee
미노믹 인터내셔널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미노믹 인터내셔널 리미티드 filed Critical 미노믹 인터내셔널 리미티드
Publication of KR20170109584A publication Critical patent/KR20170109584A/ko
Application granted granted Critical
Publication of KR102435383B1 publication Critical patent/KR102435383B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G01N33/57434—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177022547A 2015-01-16 2015-01-16 글리피칸 에피토프 및 이의 용도 Active KR102435383B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU2015/000019 WO2016112423A1 (en) 2015-01-16 2015-01-16 Glypican epitopes and uses thereof

Publications (2)

Publication Number Publication Date
KR20170109584A KR20170109584A (ko) 2017-09-29
KR102435383B1 true KR102435383B1 (ko) 2022-08-24

Family

ID=56405046

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177022547A Active KR102435383B1 (ko) 2015-01-16 2015-01-16 글리피칸 에피토프 및 이의 용도

Country Status (11)

Country Link
US (3) US20180002391A1 (enExample)
EP (1) EP3245219B1 (enExample)
JP (1) JP6735005B2 (enExample)
KR (1) KR102435383B1 (enExample)
CN (1) CN107531755B (enExample)
AU (1) AU2015376851B2 (enExample)
CA (1) CA2973771A1 (enExample)
DK (1) DK3245219T3 (enExample)
ES (1) ES2805085T3 (enExample)
SG (1) SG11201705808XA (enExample)
WO (1) WO2016112423A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703006QA (en) * 2014-10-23 2017-05-30 Minomic Internat Ltd Monoclonal ανίί-gpc-l antibodies and uses thereof
CA2983311A1 (en) * 2015-04-20 2016-10-27 Minomic International Ltd. Therapeutic antibodies and uses thereof
WO2018199318A1 (ja) * 2017-04-28 2018-11-01 国立大学法人高知大学 抗ｇｐｃ－１抗体
EP3883971A1 (en) 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN111187350A (zh) * 2019-12-30 2020-05-22 西安英创生物技术有限公司 一种与磷脂酰肌醇蛋白聚糖-1结合的抗原结合蛋白
IT202200021546A1 (it) 2022-10-19 2024-04-19 Centro Di Riferimento Oncologico Di Aviano Anticorpo monoclonale anti-GPC1, suoi usi terapeutici e diagnostici
WO2025202359A1 (en) * 2024-03-27 2025-10-02 Adcendo Aps Anti-gpc1 antibodies and uses thereof
WO2025202361A1 (en) * 2024-03-27 2025-10-02 Adcendo Aps Anti-gpc1 antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1999037764A2 (en) * 1998-01-27 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie New members of the glypican gene family
CA2346264A1 (en) * 1998-10-16 2000-04-27 Regents Of The University Of California Glypicans for the detection and treatment of human carcinoma
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
ES2312586T3 (es) * 2001-06-22 2009-03-01 Chugai Seiyaku Kabushiki Kaisha Inhibidor del crecimiento celular que contenga un anticuerpo anti-clipicano 3.
PL1674111T3 (pl) * 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Przeciwciała anty-glipikan 3
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2010019250A2 (en) 2008-08-11 2010-02-18 Solarflare Communications, Inc. Method of synchronization for low power idle
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Antibody HPA30571", The Human Protein ATLAS, https://www.proteinatlas.org/ENSG00000063660-GPC1/antibody
Uniprot Accession Number P35052, 01 Feb. 1994.

Also Published As

Publication number Publication date
WO2016112423A1 (en) 2016-07-21
EP3245219A4 (en) 2018-06-06
ES2805085T3 (es) 2021-02-10
US20210107958A1 (en) 2021-04-15
JP2018504903A (ja) 2018-02-22
JP6735005B2 (ja) 2020-08-05
US20240247037A1 (en) 2024-07-25
AU2015376851B2 (en) 2020-07-09
CN107531755A (zh) 2018-01-02
EP3245219B1 (en) 2020-04-08
CA2973771A1 (en) 2016-07-21
US20180002391A1 (en) 2018-01-04
KR20170109584A (ko) 2017-09-29
EP3245219A1 (en) 2017-11-22
DK3245219T3 (da) 2020-06-29
SG11201705808XA (en) 2017-08-30
CN107531755B (zh) 2022-02-25
AU2015376851A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
KR102435383B1 (ko) 글리피칸 에피토프 및 이의 용도
JP7479435B2 (ja) 癌治療および判断ターゲットとしてのｌｙ７５
JPWO2004081047A1 (ja) モノクローナル抗体及びこれを産生するハイブリドーマ
CN107001453B (zh) 结合人p53线性表位的抗体及其诊断应用
US12559548B2 (en) Antibodies to misfolded TDP-43 and methods of use
JP2010537625A (ja) ゲルゾリン結合剤組成物およびその使用
KR20160065876A (ko) 췌장 종양의 검출 방법, 항체 및 췌장 종양 검출용 키트
JP2019510506A (ja) 抗ポドカリキシン様タンパク質前駆体サブタイプ２モノクローナル抗体とその生成方法及び使用
WO2015048929A1 (en) Biomarkers for breast cancer
JP7053058B2 (ja) グリピカンエピトープおよびその使用
JP2025506203A (ja) 抗ｈｅｒ２／ｎｅｕ抗体および使用方法
EP2310414A1 (en) Pax 5 monoclonal antibody
JP6861349B2 (ja) Ｃｄ８１ ｌｅｌ特異的モノクローナル抗体
WO2012124334A1 (ja) 抗体、乳がんの治療に用いられる医薬組成物、腫瘍検査方法、及び、腫瘍検査用試薬
CN108727493B (zh) 抗Stathmin单克隆抗体及其用途
HK1238267B (en) Glypican epitopes and uses thereof
CN116041471A (zh) 一种抗ifitm3n端缺失21个氨基酸的截短蛋白的多克隆抗体
HK1241896A1 (en) Antibody binding a linear epitope of human p53 and diagnostic applications thereof

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000